

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Cryofocus Medtech (Shanghai) Co., Ltd.

康豐生物科技(上海)股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 6922)

(1) POLL RESULTS OF THE 2025 FIRST EXTRAORDINARY GENERAL MEETING HELD ON OCTOBER 31, 2025;

(2) AMENDMENTS TO ARTICLES OF ASSOCIATION AND

(3) ABOLISHMENT OF THE SUPERVISORY COMMITTEE

The Board is pleased to announce that all the proposed resolutions as set out in the EGM Notice were duly passed by the Shareholders by way of poll at the EGM.

Reference is made to the notice (the “**EGM Notice**”) and the circular (the “**Circular**”) of the 2025 first extraordinary general meeting (the “**EGM**”) of Cryofocus Medtech (Shanghai) Co., Ltd. (the “**Company**”) both dated October 14, 2025. Unless the context otherwise requires, capitalized terms used herein shall have the same meanings as those defined in the Circular.

The EGM was convened at 10:00 a.m. on Friday, October 31, 2025 at 3rd Floor, Building 25, Lane 3399, Kangxin Road, Pudong New Area, Shanghai, the PRC. The EGM was convened by the Board in accordance with the Company Law of the PRC and the Articles of Association, and was chaired by Mr. ZHU Jun, an executive Director and the general manager of the Company.

ATTENDANCE AT THE EGM

As at the date of the EGM, the total number of issued Shares was 239,110,000 Shares, comprising 143,438,579 H Shares and 95,671,421 Unlisted Shares. The holders of all such Shares were entitled to attend and vote for or against or abstain from voting on all the resolutions proposed at the EGM. Shareholders holding an aggregate of 131,774,144 Shares (comprising 46,044,572 H Shares and 85,729,572 Unlisted Shares), representing approximately 55.11% of the total issued Shares, attended the EGM either in person or by proxy.

To the best knowledge, information and belief of the Company: (1) there were no Shares entitling the Shareholders to attend and abstain from voting in favor of the resolutions proposed at the EGM as set out in Rule 13.40 of the Listing Rules; (2) no Shareholder was required under the Listing Rules to abstain from voting on the resolutions proposed at the EGM; and (3) no Shareholder has stated his/her/its intention to vote against or to abstain from voting on any of the resolutions proposed at the EGM. There were no Shares actually voted but excluded from calculating the poll results of the resolutions proposed at the EGM.

All the proposed resolutions as set out in the EGM Notice were voted by way of poll at the EGM. The Company's H share registrar in Hong Kong, Computershare Hong Kong Investor Services Limited, and the Company acted as the scrutineers at the EGM for the purpose of vote-taking.

All Directors, namely, Mr. LI Kejian, Mr. ZHU Jun, Mr. LIU Wei, Mr. LV Shiwen, Mr. ZHAO Chunsheng, Dr. GAO Dayong, Mr. LIANG Hsien Tse Joseph, Dr. QIN Zheng and Dr. HU Henan, attended the EGM either in person or through electronic means.

POLL RESULTS OF THE EGM

The poll results in respect of the resolutions proposed at the EGM are as follows:

Special Resolutions		Number of Votes (Approximate Percentage of the Total Number of Votes Cast)		
		For	Against	Abstain
1.	To consider and approve the proposed amendments to the Articles of Association and the abolishment of the Supervisory Committee.	131,774,144 (100%)	0 (0%)	0 (-)
2.	To consider and approve the proposed abolishment of the Rules of Procedure for the Board Meetings of the Company.	131,774,144 (100%)	0 (0%)	0 (-)
3.	To consider and approve the proposed abolishment of the Rules of Procedure for the Shareholders' Meetings of the Company.	131,774,144 (100%)	0 (0%)	0 (-)
As more than two-thirds of the votes were cast in favor of the resolutions numbered 1 to 3, all of the above resolutions were duly passed as special resolutions.				

Note: Pursuant to the Articles of Association, an abstention, or an abstention from voting, shall not be counted in computing the result of that vote.

AMENDMENTS TO ARTICLES OF ASSOCIATION

The proposed resolution on the amendments to the Articles of Association was duly passed at the EGM, and the proposed amendments to the Articles of Association have become effective from the date of the EGM. The revised Articles of Association will also be published on the websites of the Stock Exchange and the Company.

ABOLISHMENT OF THE SUPERVISORY COMMITTEE

The proposed resolution on the abolishment of the Supervisory Committee was duly passed at the EGM. With effect from the date of the EGM, the Supervisory Committee was abolished, following which the Audit Committee will exercise the powers of the Supervisory Committee as prescribed by the Company Law, and the Rules of Procedure for the Supervisory Committee and other relevant regulations shall be abolished accordingly. Each of the supervisors of the Company (the "Supervisors" and each a "Supervisor") has resigned as a Supervisor with effect from the date of the EGM, and confirmed that he or she had no disagreement with the Board or the Supervisory Committee during his or her service period. There is no matter relating to the resignation of the Supervisors that needs to be brought to the attention of the Shareholders or the Stock Exchange.

The Board would like to express their heartfelt gratitude to all the Supervisors for their valuable contribution to the Company during their tenure as Supervisors.

By Order of the Board
Cryofocus Medtech (Shanghai) Co., Ltd.
Mr. LI Kejian
Chairman of the Board

Hong Kong, October 31, 2025

As at the date of this announcement, the Board comprises Mr. LI Kejian, Mr. ZHU Jun and Mr. LIU Wei as executive Directors, Mr. LV Shiwen and Mr. ZHAO Chunsheng as non-executive Directors, and Dr. GAO Dayong, Mr. LIANG Hsien Tse Joseph, Dr. QIN Zheng and Dr. HU Henan as independent non-executive Directors.